Passage Bio, INC Form 4 insider transactions

Passage Bio and Remix Therapeutics announce a merger aimed at advancing Remix's RNA processing platform and oncology drug candidates, with a concurrent $100M financing.

Lynx1 Capital Management LP and Weston Nichols report acquiring a significant stake in Passage BIO, Inc. through multiple share purchases.

Passage Bio and Remix Therapeutics have entered into a definitive merger agreement, supported by a $100M private placement, to advance RNA-targeted therapies.

Passage Bio and Remix Therapeutics have entered into a definitive merger agreement to combine in an all-stock transaction, with the combined company focusing on Remix's RNA-targeted small molecule pipeline.

Director Dolan Sondhi acquired stock options for 10,539 shares of Passage BIO, Inc. (PASG) with an exercise price of $5.08, vesting under specific service conditions.

Passage BIO reports a Form 4 filing detailing director Derrell Porter's acquisition of stock options.

Thomas Richard Kassberg, a Director at Passage BIO, Inc., acquired 10,539 stock options on May 19, 2026, with an exercise price of $5.08.

Passage BIO, Inc. reports that Director Sandip Kapadia acquired stock options on May 19, 2026, as detailed in a Form 4 filing.

Maxine Gowen, a Director at Passage BIO, Inc., was granted a stock option for 10,539 shares with an exercise price of $5.08.

Director Athena Countouriotis acquired 10,539 stock options in Passage BIO, Inc. on May 19, 2026, with an exercise price of $5.08.

Passage Bio's President and CEO, William Chou, reported the acquisition of 10,000 shares from RSU vesting and the subsequent sale of 4,076 shares to cover tax withholdings.

Passage Bio's CFO, Kathleen Borthwick, converted 5,000 restricted stock units into common stock and subsequently sold 2,062 shares to cover tax obligations.

Passage Bio's CFO, Kathleen Borthwick, was granted 10,000 restricted stock units, vesting over two years.

Passage Bio's President and CEO, William Chou, was granted 20,000 restricted stock units, vesting over two years.

Lynx1 Capital Management LP, a 10% owner and director, increased its beneficial ownership in Passage BIO, Inc. through multiple common stock purchases in mid-September 2025.

Lynx1 Capital Management LP, a 10% owner and director, significantly increased its beneficial ownership in Passage BIO, Inc. through multiple common stock purchases in late July 2025, following a 1-for-20 reverse stock split.

OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, significant shareholders and directors of Passage BIO, Inc., reported the sale of 583,657 shares of common stock over three days in late June 2025.

Passage Bio, Inc. Director Sandip Kapadia was granted 201,857 stock options with an exercise price of $0.3598, vesting on the earlier of the one-year anniversary of the grant or the 2026 Annual Meeting.

Passage Bio, Inc. Director Maxine Gowen was granted 201,857 stock options with an exercise price of $0.3598, vesting on the earlier of the one-year anniversary of the grant or the 2026 Annual Meeting.

Passage Bio, Inc. announced that Director Athena Countouriotis was granted 201,857 stock options with an exercise price of $0.3598, vesting on the earlier of the one-year anniversary of the grant or the 2026 Annual Meeting.

Passage Bio, Inc. Director Derrell Porter was granted 201,857 stock options with an exercise price of $0.3598, vesting over one year or by the 2026 Annual Meeting.

Passage Bio, Inc. Director Saqib Islam was granted 201,857 stock options with an exercise price of $0.3598, vesting on the earlier of one year from the grant date or the 2026 Annual Meeting.

Passage Bio, Inc. director Dolan Sondhi was granted 201,857 stock options with an exercise price of $0.3598, vesting on the earlier of the one-year anniversary of the grant or the 2026 Annual Meeting.

Passage BIO, Inc. Director Thomas Richard Kassberg was granted 143,789 stock options with an exercise price of $0.3598, vesting based on service and company milestones.

OrbiMed Advisors LLC, a significant shareholder of Passage Bio, Inc., has sold a portion of its holdings in a series of transactions, reducing its indirect beneficial ownership.

OrbiMed Advisors LLC reports the sale of Passage Bio, Inc. common stock over three days, reducing its beneficial ownership.

Kathleen Borthwick, CFO of Passage Bio, Inc., reports the acquisition of employee stock options.

William Chou, CEO of Passage Bio, Inc., was granted 779,533 employee stock options on March 15, 2025, according to a Form 4 filing with the SEC.

Edgar B. Cale, General Counsel & Corporate Secretary of Passage Bio, Inc., reports the acquisition of employee stock options.

CFO Kathleen Borthwick reports acquisition of shares through RSU conversion and a sale to cover tax obligations.